MITCHELL et al v. KENVUE, INC.

3:24-cv-04109NjdFeb 24, 2026

Full text

NOT FOR PUBLICATION
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
ETHEL MITCHELL et al.,
Plaintiffs,
v.
KENVUE, INC., and JOHNSON & JOHNSON
CONSUMER INC.,
Defendants.
Civil Action No. 24-4109 (GC) (JBD)
OPINION
CASTNER, District Judge
THIS MATTER comes before the Court upon Defendants Kenvue, Inc. and Johnson &
Johnson Consumer Inc. (Johnson & Johnson)’s Motion to Dismiss Plaintiffs’ Consolidated Class
Action Complaint (ECF No. 59) pursuant to Federal Rule of Civil Procedure (Rule) 12(b)(1) and
12(b)(6). (ECF No. 60.)1 Plaintiffs opposed the Motion, and Defendants replied. (ECF Nos. 63,
65.) Defendants also filed five Notices of Supplemental Authority, and Plaintiffs responded to the
third Notice. (ECF Nos. 66, 69, 70, 72, 76, 77.) Plaintiffs filed their own Notice of Supplemental
Authority. (ECF No. 74.) The Court has carefully reviewed the parties’ submissions and decides
the matter without oral argument pursuant to Rule 78(b) and Local Civil Rule 78.1(b). 	For the
reasons set forth below, and other good cause shown, Defendants’ Motion is GRANTED.
1 	Plaintiffs are Alan Montenegro, Melissa Medina, Brenda Morgan, Cheryl Powers, Jenny
Qu, Daniel Feldtkeller, Leslie LaMay, Kayleigh Schenider, Verunika Dujmovic, Abdallah Al-
Qudsi, Marilyn Saavedra, Johne Conte, Starnella Harder, Alexandra Donato, Joseph Long, Noah
Long, Robin Corey, Daniel Calzado, Ethel Mitchell, Annette Haggerty, Paulette Williams, Ashly
Jones, and Basim Johnson. (ECF No. 59 ¶¶ 8-30.)
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 1 of 37 PageID:
<pageID>
2
I. 	BACKGROUND
A. 	Factual Background2
Defendant Johnson & Johnson, a citizen of Delaware with its principal place of business
in New Jersey, sells benzoyl peroxide (BPO) acne treatment products under the brand names Clean
& Clear and Neutrogena. 	(ECF No. 59 ¶¶ 1, 33.)3 	Defendant Kenvue, Inc. is a subsidiary of
Johnson & Johnson and “shares responsibility for consumer health products including brands
Clean and Clear and Neutrogena.” (Id. ¶ 34.)4 Plaintiffs reside in eleven states, and each Plaintiff
purchased at least one of Defendants’ BPO products. 	(Id. ¶¶ 1, 8-32.)5 	Those BPO products
include Clean & Clear Continuous Control Acne Cleanser; Clean & Clear Persa-Gel® 10; Clean
& Clear Continuous Control Benzoyl Peroxide Acne Face Wash; Neutrogena Rapid Clear
Stubborn Acne Spot Gel; Neutrogena Stubborn Acne AM Treatment; Neutrogena Stubborn Marks
2 	On a motion to dismiss under Rule 12(b)(6), the Court must accept all facts as true, but
courts “are not bound to accept as true a legal conclusion couched as a factual allegation.” Bell
Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (internal citation and quotations omitted).
3 	Page numbers for record cites (i.e., “ECF Nos.”) refer to the page numbers stamped by the
Court’s e-filing system and not the internal pagination of the parties.
4 	In a footnote, Defendants argue Kenvue, Inc. should be dismissed from this action because
“Plaintiffs’ allegations lump[] [both Defendants together] and misrepresent[] [Kenvue, Inc.’s]
relationship with Johnson & Johnson, a company with which Defendants have no current
affiliation.” (ECF No. 60-1 at 12 n.1). The Court will not dismiss Kenvue, Inc. for these reasons
at this early stage. See McMahon v. Volkswagen Aktiengesellschaft, Civ. No. 22-1537, 2023 WL
4045156, at *10 (D.N.J. June 16, 2023) (“Though there are multiple entities involved, when these
entities are intertwined through a complex corporate structure, plaintiffs cannot be expected to
know the exact corporate structure and degree of each defendant's involvement at the motion to
dismiss stage and prior to discovery.”) (internal quotation marks and citations omitted) (alterations
adopted). To the extent Defendants also request Johnson & Johnson Consumer Inc. be replaced
with Kenvue Brands LLC—the subsidiary of Kenvue, Inc.—the Court is not persuaded
substitution at this time is appropriate. (See ECF No. 60-1 at 12.) Defendants may file a separate
motion to substitute.
5 	Plaintiffs reside in California, Connecticut, Illinois, Maryland, Missouri, Nevada, New
York, Ohio, Pennsylvania, Texas, and Washington. (ECF No. 59 ¶¶ 8-30.)
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 2 of 37 PageID:
<pageID>
3
PM 	Treatment; 	Neutrogena 	On-the-Spot 	Acne 	Treatment; 	and 	Neutrogena 	Clear 	Pore
Cleanser/Mask. (Id. ¶¶ 1 n.1, 8-32.) Plaintiffs allege that because BPO naturally degrades into
benzene, “under normal storage and transport conditions,” all of the BPO products they purchased
contain benzene, a known human carcinogen. (Id. ¶¶ 1, 8.) Defendants did not disclose that these
products contain benzene or that the BPO in the products degrade into benzene. 	(Id. ¶¶ 7-8.)
Plaintiffs allege they would not have purchased these products, or paid less for them, had this
information been disclosed. (Id. ¶ 31.)
1. 	The BPO Products and the Danger of Benzene
The products at issue are each manufactured in the same way. (Id. ¶ 41.) Defendants mix
BPO, a dry white powder, with other ingredients to create the topical creams, cleansers, scrubs,
and washes used to treat acne. (Id. ¶ 42.) BPO constitutes up to 10% of the total composition of
these products. (Id.) Defendants list the ingredients, including BPO, on the product labels, but
the labels do not state that the products contain benzene or can degrade to form benzene. 	(Id.
¶ 70.) 	Instead, the labels warn users to, among other things, “avoid contact with the eyes, lips,
and mouth,” and “[p]rotect from excessive heat (40°C/104°F)[.]” (Id. ¶ 116.)
The health hazards of benzene have been recognized for over one hundred years. (Id. ¶ 46.)
Plaintiffs allege that the scientific and regulatory communities agree that benzene is a well-known
human carcinogen with severe consequences to human exposure. (Id.; see also id. ¶¶ 47-51, 58-
60 (citing examples).) In response to reports of benzene contamination in various drug products,
the United States Food and Drug Administration (FDA) published guidance on its website on
December 27, 2023. 	(Id. ¶ 54; see also id. ¶¶ 73-75.) 	The guidance stated that “[d]rug
manufacturers with a risk for benzene contamination should test their drugs accordingly and should
not release any drug product batch that contains benzene above 2 [parts per million (ppm)]” and
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 3 of 37 PageID:
<pageID>
4
“[i]f any drug product batches with benzene above 2 ppm are already in distribution, the
manufacturer should contact FDA to discuss the voluntary initiation of a recall[.]”) (Id.)
Studies dating back to as early as 1936 have found that BPO degrades into benzene when
exposed to heat over time. (Id. ¶¶ 104-110.) In 2024, studies connected this finding to BPO acne
products in particular. On March 5, 2024, Valisure LLC submitted a Citizen Petition to the FDA
requesting a suspension of sales and recall of BPO acne products from the U.S. market based on
its findings that numerous BPO acne products contained elevated levels of benzene. (Id. ¶ 62.)6
Valisure is a company that operates an “analytical laboratory” and is registered with the Durg
Enforcement Administration. (Id. ¶ 63.) It reported analyzing sixty-six acne drug products, both
prescription and over-the-counter (OTC), that contained BPO. (Id. ¶¶ 43, 67.) Valisure incubated
each of the products at 122°F and measured samples at various intervals across an 18-day period.
(Id.) 	Valisure noted 122°F was a reasonable temperature because it is “an accepted incubation
temperature used by the pharmaceutical industry” and is a temperature that “the product may be
exposed to during distribution and handling by consumers.” (Id. at 37 n.42.) Plaintiffs allege that
the study revealed that each of the sixty-six products, including Defendants’ BPO products,
contained benzene. 	(Id. ¶¶ 43, 67.) 	Based on its study, Valisure concluded that “[o]n-market
formulations of BPO containing acne treatment products tested by Valisure appear to be
fundamentally unstable and generally form unacceptably high levels of benzene.” (ECF No. 60-2
at 47.) 	Most Plaintiffs purchased a type of Neutrogena BPO acne treatment product for which
6 	The Court may consider the Valisure Citizen Petition, (ECF No. 60-2), because it is an
“undisputedly authentic document that [D]efendant[s] attach[] as an exhibit to a motion to dismiss
[and Plaintiffs’] claims are based on the document.” Pension Benefit Guar. Corp. v. White Consol.
Indus., Inc., 998 F.2d 1192, 1196 (3d Cir.1993); see also, e.g., Navarro v. Walgreens Boots All.,
Inc., Civ. No. 24-00290, 2025 WL 1411406, at *2 n.1 (E.D. Cal. May 15, 2025) (“Plaintiffs have
unambiguously incorporated Valisure’s [C]itizen [P]etition into the first amended complaint.”),
report and recommendation adopted, 2025 WL 3485004 (E.D. Cal. Dec. 4, 2025).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 4 of 37 PageID:
<pageID>
5
Valisure testing revealed benzene levels surpassing 2 ppm. 	The remainder of the Plaintiffs
purchased (1) Clean & Clear BPO acne treatment products for which Valisure testing revealed
benzene levels below 2 ppm; or (2) Neutrogena or Clean & Clear BPO acne treatment products
that Valisure did not test. 	(See ECF No. 59 ¶¶ 1 n.1, 8-30; ECF No. 60-2 at 40.) Apart from
Valisure-specific testing, Plaintiffs further allege that their counsel purchased some of Defendants’
BPO products for which independent testing showed benzene levels above 2 ppm. (ECF No. 59
¶ 69.)
On March 11, 2025, the FDA issued a recall of certain BPO products. (Id. ¶ 55.) The FDA
concluded that a limited number of the tested products should be recalled at the retail level,
meaning that retailers were instructed to remove the products from store shelves and online
marketplaces, but consumers who had already purchased the products were not instructed to take
action because “[e]ven with daily use of these products for decades, the risk of a person developing
cancer because of exposure to benzene found in these products is very low.” (ECF No. 60-2 at 6.)
None of Defendants’ BPO products purchased by Plaintiffs are listed in the FDA recall. (See id at
6-8.)
2. 	The Regulatory Scheme
The Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations set
forth the requirements for the branding and selling of OTC drugs. 	Plaintiffs allege Defendants
violated four statutory or regulatory sources of FDCA authority: (1) the Acne Monograph; (2) the
format and content labeling requirements; (3) Chapter V of the FDCA; and (4) current good
manufacturing practices.7 (See ECF No. 59 ¶¶ 72, 78, 81-84, 89, 90, 92, 95, 120-127; see also
ECF No. 63 at 15-26.)
7 	The FDCA provides no private right of action, see In re Orthopedic Bone Screw Prods.
Liab. Litig., 193 F.3d 781, 788 (3d Cir. 1999), and contains a broad express preemption provision
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 5 of 37 PageID:
<pageID>
6
a. 	Acne Monograph
The FDCA regulates most OTC medications through a “monograph” process. 	A
monograph is a set of regulations describing conditions under which certain drugs may be
marketed without a prescription. See 21 C.F.R. § 330.10, et seq. “Like a recipe, each monograph
sets out the FDA-approved active ingredients for a given therapeutic class of OTC drugs and
provides the conditions under which each active ingredient is [generally recognized as safe and
effective.]” Nat. Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 710 F.3d 71, 74-75 (2d Cir.
2013). “Any product which fails to conform to an applicable monograph after its effective date is
liable to regulatory action.” 21 C.F.R. § 330.10(b).
There is a monograph specific to OTC acne products. 	In 2010, the FDA issued a “final
rule to include [BPO] as a generally recognized as safe and effective . . . active ingredient in [OTC
acne] topical drug products.” 	(ECF No. 59 ¶ 82 (quoting 75 Fed. Reg. 9767, 9767 (March 4,
2010).) This monograph has been incorporated into the regulations. See 21 C.F.R. §§ 333.301-
333.350 (Acne Monograph). The Acne Monograph expressly permits the use of BPO as an active
ingredient in products in an amount of 2.5 to 10 percent. Id. § 333.310(a). The Acne Monograph
also imposes labeling and warning requirements. For products that include BPO, the regulations
outline specific warnings that must be included on labels, but there is no requirement to disclose
the possibility of benzene. See id. § 333.350(c)(1), (4). Despite the FDA-issued guidance in 2023
on drug products containing benzene above 2 ppm and the 2025 recall, the Acne Monograph has
not been changed.
applicable to the instant matter, 21 U.S.C. § 379r(a). Accordingly, whether Plaintiffs’ Consolidated
Class Action Complaint survives Defendants’ Motion to Dismiss boils down to whether Plaintiffs
plead a violation of any statutory or regulatory authority under the FDCA that has a parallel state
law requirement. See supra Section III.B.
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 6 of 37 PageID:
<pageID>
7
The Acne Monograph also provides that an “over-the-counter acne drug product . . . is
generally recognized as safe and effective and is not misbranded if it meets each of the conditions
in [the Acne Monograph] and each general condition established in [21 C.F.R.] § 330.1.” 	Id.
§ 333.301. 	In other words, in addition to the requirements specific to the Acne Monograph,
Defendants must also adhere to the general requirements of 21 C.F.R. § 330.1. That section, in
turn, sets forth three relevant requirements. 	First, the product must be “labeled in compliance
with . . . the format and content requirements in [21 C.F.R.] § 201.66.” 21 C.F.R. § 330.1(c)(1).
Second, the product must also be “labeled in compliance with chapter V of the [FDCA.]” 	Id.
Third, the product must be “manufactured in compliance with current good manufacturing
practices, as established by parts 210 and 211 of this chapter.” Id. § 330.1(a). Failure to comply
with any of these requirements renders the product “liable to regulatory action.” Id. § 330.1. The
Court briefly turns to each of these three requirements.
b. 	Format and Content Labeling Requirements
Section 201.66 lists “[f]ormat and content” labeling requirements for OTC drugs. 	21
C.F.R. § 201.66. In particular, the regulation mandates that active and inactive ingredients be listed
on OTC drug labels. Id. § 201.66(c)(2), (c)(8).
c. 	Chapter V of the FDCA
Chapter V of the FDCA prohibits the sale of “adulterated” or “misbranded” drugs. 	21
U.S.C § 331(a)-(b). A drug is “adulterated” if it “consists in whole or in part of any filthy, putrid,
or decomposed substance,” 21 U.S.C § 351(a)(1), or if “the methods used in, or the facilities or
controls used for, [the drug’s] manufacture, processing, packing, or holding do not conform to or
are not operated or administered in conformity with current good manufacturing practice[s],” id.
§ 351(a)(2)(B). A drug is “misbranded” “[i]f its labeling is false or misleading in any particular.”
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 7 of 37 PageID:
<pageID>
8
Id. § 352(a)(1). The labeling is “misleading” if it “fails to reveal facts . . . material with respect to
consequences which may result from the use of the article to which the labeling or advertising
relates . . . under such conditions of use as are customary or usual.” 21 U.S.C § 321(n).
d. 	Current Good Manufacturing Practices
Current good manufacturing practices, known as cGMPs, “require OTC drug products
meet safety, quality, purity, identity, and strength standards.” 	Navarro v. Walgreens Boots All.,
Inc., Civ. No. 24-00290, 2025 WL 1411406, at *1 (E.D. Cal. May 15, 2025), report and
recommendation adopted, 2025 WL 3485004 (E.D. Cal. Dec. 4, 2025). Sections 210 and 211, in
turn, outline the cGMPs. 	For example, OTC drug manufacturers must have “a written testing
program designed to assess the stability characteristics of drug products” and must use the results
of stability testing to determine “appropriate storage conditions and expiration dates.” 21 C.F.R.
§ 211.166(a).
B. 	Procedural Background
Shortly after Valisure submitted its Citizen Petition to the FDA on March 5, 2024, Plaintiffs
Ethel Mitchell and Annette Haggerty filed a putative class action complaint. 	(ECF No. 1.) 	On
April 28, 2025, the Court consolidated this case with two others originally filed in the United States
District Courts for the Central District of California and the Western District of Missouri. (ECF
No. 53.) On May 22, 2025, Plaintiffs filed the operative Consolidated Class Action Complaint.
(ECF No. 59.) 	Plaintiffs seek to represent a multi-state class of “consumers who purchased
Neutrogena and/or Clean & Clear [BPO] products in the United States of America and its territories
from March 8, 2020 to the present for personal or household use within the applicable limitations
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 8 of 37 PageID:
<pageID>
9
period.” (Id. ¶ 137.) In the alternative, Plaintiffs seek to represent a subclass of persons residing
in their state. (Id. ¶ 138.)8
In their eight count Consolidated Class Action Complaint, Plaintiffs bring claims for
violations of the Unfair Competition Law, Cal. Bus. & Prof. Code § 17200, et seq. (Count I) and
the Consumers Legal Remedies Act, Cal. Bus. & Prof. Code § 1750, et seq. (Count II); false
advertising under various state statutes (Count III)9; deceptive trade practices under various state
statutes (Count IV)10; breach of the implied warranty of merchantability (Count V); negligent
misrepresentation or omission (Count VI); unjust enrichment (Count VII); and breach of express
warranty (Count VIII). (Id. ¶¶ 147-248.)11
Plaintiffs seek injunctive, declaratory, and monetary relief. (Id. at 103-104.) Plaintiffs seek
an order (1) enjoining Defendants from selling the BPO products or suggesting that they are safe
for human application and (2) requiring Defendants to engage in a corrective advertising
campaign. (Id. at 104.) Plaintiffs also seek “an order awarding declaratory relief, and any further
8 	Plaintiffs do not appear to seek a subclass of persons residing in Connecticut. (ECF No.
59 ¶ 138.)
9 	Plaintiffs cite the California False Advertising Law, Cal. Bus. & Prof. Code § 17500, et
seq., and the New York General Business Law, N.Y. Gen. Bus. Law § 350, et seq. (ECF No. 59
¶¶ 180-181.)
10 	Plaintiffs cite the California Consumer Legal Remedies Act, Cal. Civ. Code § 1750, et seq.;
the Illinois Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505/1, et seq.; the
Maryland Unfair or Deceptive Trade Practices Act, Md. Code Com. Law § 13-301, et seq.; the
Missouri Merchandising Practices Act, Mo. Rev. Stat. § 407, et seq.; the Nevada Deceptive Trade
Practice Act, Nev. Rev. Stat. § 598.0903, et seq.; the New York General Business Law, N.Y. Gen.
Bus. Law § 349, et seq.; the Ohio Consumer Sales Practices Act, Ohio Rev. Code § 1345.01, et
seq.; the Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S. § 201-1, et
seq.; the Texas Unfair Trade Practices and Consumer Protection Law, Tex. Bus. & Com. Code §
17.41, et seq.; and the Washington Consumer Protection Act, Wash. Rev. Code § 19.86.010, et
seq. (ECF No. 59 ¶¶ 191-200.)
11 	The Court has subject matter jurisdiction under 28 U.S.C. §§ 1332(d)(2).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 9 of 37 PageID:
<pageID>
10
retrospective or prospective injunctive relief permitted by law or equity . . . .” (Id.) 	Finally,
Plaintiffs seek compensatory and punitive damages, restitution, and attorneys’ fees. (Id.)
II. 	LEGAL STANDARD
A. 	Rule 12(b)(1)
Rule 12(b)(1) permits a defendant to move at any time to dismiss the complaint for lack of
subject-matter jurisdiction on either facial or factual grounds. Gould Elecs. Inc. v. United States,
220 F.3d 169, 176 (3d Cir. 2000).
A facial challenge asserts that “the complaint, on its face, does not allege sufficient grounds
to establish subject matter jurisdiction.” 	Iwanowa v. Ford Motor Co., 67 F. Supp. 2d 424, 438
(D.N.J. 1999). In analyzing a facial challenge, a court “must only consider the allegations of the
complaint and documents attached thereto, in the light most favorable to the plaintiff.” 	Gould
Elecs. Inc., 220 F.3d at 176. “A court considering a facial challenge construes the allegations in
the complaint as true and determines whether subject matter jurisdiction exists.” 	Arosa Solar
Energy Sys., Inc. v. Recom Solar, LLC, Civ. No. 18-1340, 2021 WL 1196405, at *2 (D.N.J. Mar.
30, 2021).
A factual challenge, on the other hand, “attacks allegations underlying the assertion of
jurisdiction in the complaint, and it allows the defendant to present competing facts.” Hartig Drug
Co. Inc. v. Senju Pharm. Co., 836 F.3d 261, 268 (3d Cir. 2016). The “trial court is free to weigh
the evidence and satisfy itself as to the existence of its power to hear the case” and “the plaintiff
will have the burden of proof that jurisdiction does in fact exist.” Petruska v. Gannon Univ., 462
F.3d 294, 302 n.3 (3d Cir. 2006) (quoting Mortensen v. First Fed. Sav. & Loan Ass’n, 549 F.2d
884, 891 (3d Cir. 1977)). 	“Therefore, a 12(b)(1) factual challenge strips the plaintiff of the
protections and factual deference provided under 12(b)(6) review.” Hartig Drug Co., 836 F.3d at
268. Regardless of the type of challenge, the plaintiff bears the “burden of proving that the court
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 10 of 37 PageID:
<pageID>
11
has subject matter jurisdiction.” Cottrell v. Heritages Dairy Stores, Inc., Civ. No. 09-1743, 2010
WL 3908567, at *2 (D.N.J. Sep. 30, 2010) (citing Mortensen, 549 F.2d at 891).
“A motion to dismiss for want of standing is . . . properly brought pursuant to Rule 12(b)(1),
because standing is a jurisdictional matter.” Ballentine v. United States, 486 F.3d 806, 810 (3d Cir.
2007). “In evaluating whether a complaint adequately pleads the elements of standing,” under a
facial challenge to standing, “courts apply the standard of reviewing a complaint pursuant to a
Rule 12(b)(6) motion to dismiss for failure to state a claim: Court[s] must accept as true all material
allegations set forth in the complaint, and must construe those facts in favor of the nonmoving
party.” In re Schering Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235, 243
(3d Cir. 2012) (alteration in original).
B. 	Rule 12(b)(6)
On a motion to dismiss for failure to state a claim upon which relief can be granted, courts
“accept the factual allegations in the complaint as true, draw all reasonable inferences in favor of
the plaintiff, and assess whether the complaint and the exhibits attached to it ‘contain enough facts
to state a claim to relief that is plausible on its face.’” Wilson v. USI Ins. Serv. LLC, 57 F.4th 131,
140 (3d Cir. 2023) (quoting Watters v. Bd. of Sch. Dirs. of Scranton, 975 F.3d 406, 412 (3d Cir.
2020)). 	“A claim is facially plausible ‘when the plaintiff pleads factual content that allows the
court to draw the reasonable inference that the defendant is liable for the misconduct alleged.’”
Clark v. Coupe, 55 F.4th 167, 178 (3d Cir. 2022) (quoting Mammana v. Fed. Bureau of Prisons,
934 F.3d 368, 372 (3d Cir. 2019)). When assessing the factual allegations in a complaint, courts
“disregard legal conclusions and recitals of the elements of a cause of action that are supported
only by mere conclusory statements.” 	Wilson, 57 F.4th at 140 (citing Oakwood Lab’ys LLC v.
Thanoo, 999 F.3d 892, 904 (3d Cir. 2021)). The defendant bringing a Rule 12(b)(6) motion bears
the burden of “showing that a complaint fails to state a claim.” In re Plavix Mktg., Sales Pracs. &
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 11 of 37 PageID:
<pageID>
12
Prod. Liab. Litig. (No. II), 974 F.3d 228, 231 (3d Cir. 2020) (citing Davis v. Wells Fargo, 824 F.3d
333, 349 (3d Cir. 2016)).
In deciding a Rule 12(b)(6) motion, the court can only consider “the complaint, exhibits
attached to the complaint, matters of public record, as well as undisputedly authentic documents
if the complainant’s claims are based upon these documents.” Mayer v. Belichick, 605 F.3d 223,
230 (3d Cir. 2010). A court may also consider any document “integral to or explicitly relied upon
in the complaint” when ruling on a motion to dismiss. In re Burlington Coat Factory Sec. Litig.,
114 F.3d 1410, 1426 (3d Cir. 1997).
When claims sound in fraud, plaintiffs “must satisfy the heightened pleading standards of
Federal Rule of Civil Procedure 9(b).” Burns v. Stratos, No. 22-1319, 2023 WL 4014474, at *2
n.3 (3d Cir. June 15, 2023) (citing Frederico v. Home Depot, 507 F.3d 188, 200 (3d Cir. 2007));
see also Fed. R. Civ. P. 9(b) (“In alleging fraud . . . , a party must state with particularity the
circumstances constituting fraud[.]”); Foglia v. Renal Ventures Mgmt., LLC, 754 F.3d 153, 155-58
(3d Cir. 2014). This ordinarily requires a plaintiff who alleges fraud to “support its allegations
‘with all of the essential factual background that would accompany the first paragraph of any
newspaper story—that is, the who, what, when, where and how of the events at issue.’” United
States ex rel. Moore & Co., P.A. v. Majestic Blue Fisheries, LLC, 812 F.3d 294, 307 (3d Cir. 2016)
(quoting In re Rockefeller Ctr. Props., Inc. Sec. Litig., 311 F.3d 198, 217 (3d Cir. 2002)); accord
Frederico, 507 F.3d at 200 (“To satisfy this standard, the plaintiff must plead or allege the date,
time and place of the alleged fraud or otherwise inject precision or some measure of substantiation
into a fraud allegation.”).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 12 of 37 PageID:
<pageID>
13
III. 	DISCUSSION
A. 	Standing
Defendants bring a facial challenge, arguing Plaintiffs lack Article III standing because
Plaintiffs do not establish that they purchased BPO products with benzene and instead rely on an
“unsupported benefit of the bargain theory” under which Plaintiffs allege they never would have
purchased the products, or would have purchased them for less, if Defendants warned about the
products. (ECF No. 60-1 at 15, 37-38.) Defendants contend that Plaintiffs lack standing to pursue
state consumer fraud claims for the same reason. (Id. at 40.) Defendants also argue that Plaintiffs
lack standing to seek injunctive or declaratory relief. 	They argue “plaintiffs seeking injunctive
relief cannot show an injury-in-fact where they are aware of the harm a product allegedly causes,
and as such, will not purchase the product in the future.” (Id. at 41.) And, according to Defendants,
Plaintiffs lack standing for restitution or disgorgement of profits because they mention these forms
of relief in only conclusory terms. (Id. at 42.)
Plaintiffs respond that they adequately allege a benefit-of-the-bargain theory, including that
they plausibly allege they purchased products containing benzene. (ECF No. 63 at 27, 31). And
Plaintiffs contend that Defendants’ argument about standing to pursue specific forms of relief is
premature because courts dismiss claims, not remedies, at the motion to dismiss stage. (Id. at 34.)
“Challenges based on the various justiciability doctrines . . . are properly brought under
[Rule] 12(b)(1).” 	Brill v. Velez, Civ. No. 13-05643, 2014 WL 2926086, at *2 (D.N.J. June 27,
2014). Article III of the United States Constitution limits a federal court’s jurisdiction to actual
cases or controversies. U.S. Const., art. III, § 2, cl. 1. The doctrine of Article III standing is “an
additional 	limitation 	on 	the 	federal 	judicial 	power 	derived 	from 	the 	case-or-controversy
requirement,” which prohibits courts from issuing “advisory opinions.” Lutter v. JNESO, 86 F.4th
111, 123-25 (3d Cir. 2023). 	“The plaintiff, as the party invoking federal jurisdiction, bears the
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 13 of 37 PageID:
<pageID>
14
burden of establishing” standing. 	Spokeo, Inc. v. Robins, 578 U.S. 330, 338 (2016) (citation
omitted). 	To have standing, a plaintiff must “allege: 1) an injury in fact; 2) causation; and 3)
redressability.” 	In re Liquid Aluminum Sulfate Antitrust Litig., Civ. No. 16-2687, 2017 WL
3131977, at *18 (D.N.J. July 20, 2017) (citing Lujan v. Defenders of Wildlife, 504 U.S. 555, 560-
61 (1992)). A plaintiff must establish standing “‘for each claim that [it] press[es] and for each
form of relief that [it] seek[s].’” Lutter, 86 F.4th at 124 (quoting TransUnion LLC v. Ramirez, 594
U.S. 413, 431 (2021)). When “all claims allege the same injury, it is proper for a Court to analyze
each claim in one collective standing analysis.” 	Grodnick v. Johnson & Johnson, Civ. No. 24-
2616, 2024 WL 5056411, at *2 n.4 (D.N.J. Dec. 10, 2024). “Injury-in-fact is comprised of three
sub-elements: (1) an invasion of a legally protected interest; (2) injury [that] is both concrete and
particularized; and (3) injury [that] is actual or imminent, not conjectural or hypothetical.” Huertas
v. Bayer US LLC, 120 F. 4th 1169, 1174 (3d Cir. 2024) (internal quotation marks and citations
omitted).
For the reasons outlined below, Plaintiffs have standing to pursue their claims for monetary
damages and restitution but not injunctive or declaratory relief.
1.	
Monetary Damages
One way “a plaintiff might successfully plead an economic injury” to satisfy the injury-in-
fact requirement is “by alleging that she bargained for a product worth a given value but received
a product worth less than that value.” 	In re Johnson & Johnson, Talcum Powder Prod. Mktg.,
Sales Pracs. & Liab. Litig., 903 F.3d 278, 283 (3d Cir. 2018). “This is known as the benefit-of-
the-bargain theory of injury.” 	Huertas, 120 F.4th at 1174. 	Under this theory, “[t]he economic
injury is calculated as the difference in value between what was bargained for and what was
received.” Johnson & Johnson, 903 F.3d at 283. To establish injury-in-fact for monetary damages
under a benefit-of-the-bargain theory, Plaintiffs must plausibly allege that (1) the products with the
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 14 of 37 PageID:
<pageID>
15
asserted defect were worth less than products without the defect and (2) Plaintiffs purchased
products that were in fact defective. See Huertas, 120 F. 4th at 1175-78.
a. 	Whether 	Plaintiffs 	Plausibly 	Allege 	that 	BPO 	Products 	with
Benzene are Worth Less than BPO Products without Benzene
In Huertas, plaintiffs brought a putative class action alleging they purchased benzene-
contaminated Lotrimin and Tinactin spray products used to treat skin infections and sought
damages under various state law causes of action. Id. at 1172-73. The defendant brought a facial
challenge contesting that the plaintiffs alleged an injury-in-fact. Id. at 1174 & n.7. The plaintiffs
argued they had standing under a benefit-of-the-bargain theory because they ‘‘bargained for an
antifungal product free of contaminants and dangerous substances but instead received products
that were unmerchantable and unfit for use as they [were] adulterated and contain[ed] harmful
levels of benzene, [which] rendered their products worthless.” 	Id. at 1175 (internal quotation
marks and citations omitted.) The Third Circuit concluded that “products that are unusable due
to . . . contamination are necessarily worth less than the product when properly manufactured.” Id.
Based on this conclusion, which required “little elaboration,” the Third Circuit found the plaintiffs
plausibly alleged that the contaminated products containing benzene were worth less than the
uncontaminated products plaintiffs thought they were purchasing. Id. at 1175, 1177-78.
The facts here are similar. Plaintiffs allege they “spent money to purchase BPO [p]roducts
they would not otherwise have purchased, or paid less for, absent Defendants’ misconduct.” (ECF
No. 59 ¶ 31.) Plaintiffs allege Defendants’ BBO products are contaminated with benzene based
on the 2024 Valisure study as well as other independent testing. (Id. ¶¶ 62-69.) These benzene-
containing products, Plaintiffs allege, were “worthless.” 	(Id. ¶¶ 6, 98, 134). 	Under Huertas,
Plaintiffs have plausibly alleged Defendants’ benzene-containing acne products are worth less than
acne products not containing benzene.
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 15 of 37 PageID:
<pageID>
16
b. 	Whether Plaintiffs Plausibly Allege They Purchased Defective
Products
“Having determined that Plaintiffs have plausibly alleged economic injury,” the Court
“must still determine whether they sufficiently alleged that their products”—i.e., Plaintiffs’
purchased products—“contained benzene.” 	Huertas, 120 F. 4th at 1178 (emphasis in original).
“Otherwise, their claim that they purchased a product worth less than the product for which they
bargained necessarily fails, and they are not entitled to relief under the benefit-of-the-bargain
theory.” Id. For the reasons described below, the Court finds Plaintiffs have sufficiently alleged
that they purchased benzene-containing products, so they have standing to pursue claims for
monetary damages.
In Huertas, the Third Circuit examined whether the plaintiffs plausibly pled that the sprays
they bought contained benzene. The plaintiffs relied on two events. First, the plaintiffs alleged
that in October 2021, the defendant voluntarily recalled certain Lotrimin and Tinactin spray
products after discovering samples of those products contained benzene. 	Id. at 1172. 	The
defendant recalled spray products “with lot numbers beginning with TN, CV, or NAA” that were
distributed between September 2018 and September 2021. Id. Second, shortly after the recall, the
plaintiffs alleged Valisure tested thirteen samples of recalled Lotrimin and Tinactin products and
found twelve—all with lot numbers beginning with TN—contained detectable benzene levels and
all but one of those samples’ levels exceeded the FDA guideline limit. 	Id. at 1172-73. 	The
plaintiffs alleged they purchased the spray products during the recall period, but only four of the
nine plaintiffs purchased from lot numbers specified in the recall. Id. at 1173.
The district court dismissed the plaintiffs’ complaint with prejudice for lack of standing.
Id. The Third Circuit reversed, finding the district court’s “reasoning was flawed” with respect to
the district court’s requirement that the plaintiffs allege “all of the representative products
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 16 of 37 PageID:
<pageID>
17
contained benzene.” 	Id. at 1178-79. 	Huertas made clear that “[p]laintiffs need only plausibly
allege that they purchased contaminated products. 	This does not require a showing that all
products in the recall were contaminated.” Id. (emphasis in original) (first citing In re Recalled
Abbott Infant Formula Prod. Liab. Litig., 97 F.4th 525, 529-30 (7th Cir. 2024) (suggesting that
injury is adequately particularized when “contamination of . . . products was sufficiently
widespread to plausibly affect any given [product], including the ones [plaintiffs] purchased”); and
then citing John v. Whole Foods Mkt. Grp., Inc., 858 F.3d 732, 734-36 (2d Cir. 2017) (holding
injury was plausibly alleged when third-party testing revealed challenged mislabeling practices
were “systematic” and “routine”)). The Third Circuit remanded the case to the district court with
respect to the plaintiffs who purchased products from the TN, CV, or NAA lot numbers “to apply
the plausibility standard.” 	Id. at 1181.12 	However, “because neither the recall itself, nor the
Valisure testing . . . have any relevance to [p]laintiffs who have failed to allege a TN, CV, or NAA
lot number,” the Third Circuit concluded the district court “properly dismissed [those specific
plaintiffs’] claims for lack of standing.” 	Id.
Here, Defendants’ arguments that Plaintiffs failed to plausibly allege they purchased
defective products are unpersuasive. First, Defendants contend that Plaintiffs do not “allege that
they purchased the same batch or lot number as the products tested.” (ECF No. 60-1 at 39.) But
this argument extends the reasoning in Huertas too far. Unlike in Huertas, this is not a case about
a specific batch gone awry from external contamination but rather concerns a problem inherent to
12 	While the case was on appeal, the defendant filed a complaint in a separate action against
the manufacturer of the component in Lotrimin and Tinactin that was contaminated with benzene
to recover costs associated with the recall. Huertas v. Bayer US LLC, 120 F. 4th 1169, 1179 (3d
Cir. 2024). 	The plaintiffs argued that complaint provided further evidence of the widespread
nature of the contamination. 	Id. at 1179-80. 	The Third Circuit instructed the district court, on
remand, to consider any motion for leave to amend so that the plaintiffs could incorporate
additional allegations into their amended pleading. Id. at 1181.
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 17 of 37 PageID:
<pageID>
18
each product that contains BPO. (See ECF No. 60-2 at 30 (Valisure Citizen Petition stating “the
specific problem with benzene in [BPO] products does not appear to be a contamination issue from
a specific ingredient, but instead the inherent instability of the [BPO] molecule that breaks down
and forms benzene.”). 	See also Huertas, 120 F.4th at 1179 (citing John, 858 F.3d at 734-36,
approvingly for notion that “systematic” problem supports plausibility of injury). Valisure tested
Defendants’ Neutrogena and Clean & Clear BPO products and those products contained benzene,
including some at levels that exceeded the FDA guideline limit. (ECF No. 60-2 at 40.) And, as
Plaintiffs allege, each of Defendants’ BPO products “are manufactured in the same manner.” (ECF
No. 59 ¶ 41.) 	Thus, “by virtue of their ‘same’ manufacturing”—and in particular the allegedly
instable BPO ingredient—“[Defendants’] BPO products are sufficiently comparable” to the ones
Plaintiffs actually purchased “to infer—at least at this motion-to-dismiss stage—that this result
would have held across the [Neutrogena and Clean & Clear] BPO acne treatment product line.”
In re Target Corp. BPO Sales & Marketing Litig., Civ. No. 24-1323, 2026 WL 145824, at *5 (D.
Minn. Jan. 20, 2026). 	In other words, it is plausible that the Neutrogena and Clean & Clear
products Plaintiffs purchased—even if Valisure did not test those specific brands of Neutrogena or
Clean & Clear products, as is the case for a minority of the Plaintiffs—“manifested the alleged
defect.” Id.
Defendants next argue that Valisure heated the BPO products, but Plaintiffs do not allege
that the products they purchased were likewise heated. 	(ECF No. 60-1 at 39-40.) 	While
Defendants are correct, they ignore Plaintiffs’ allegation that the products were heated to
“perform[] accelerated stability studies” and at a temperature to replicate standard distribution and
handling conditions by consumers. (ECF No. 59 at 37 n.2.) In other words, drawing all inferences
in Plaintiffs’ favor as the Court must, Plaintiffs allege Valisure used a standard procedure to
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 18 of 37 PageID:
<pageID>
19
replicate the degradation of BPO into benzene over the course of the tested products’ shelf life.
Other courts that have addressed this argument—in the context of other BPO products in the
Valisure study—have found similarly. See, e.g., Target Corp., 2026 WL 145824, at *5 (“Valisure’s
incubation testing replicated real-world distribution and consumer-handling conditions and was
consistent with pharmaceutical industry testing standards.”); Howard v. Alchemee, LLC, Civ. No.
24-01834, 2024 WL 4272931, at *4 (C.D. Cal. Sep. 19, 2024) (“Plaintiffs allege that. . . BPO
degrades to benzene under normal conditions . . . .”).
And regardless of the incubation testing, the Valisure study demonstrates that each of
Defendants’ Neutrogena and Clean & Clear products in the study had some level of benzene on
day 0, before the incubation took place. (See ECF No. 60-2 at 40.) See also Target Corp., 2026
WL 145824, at * 5 (“As Valisure explained in its Citizen Petition, Valisure found ‘native benzene’
present in 94 of the 99 products it tested . . . including all three Up&Up products Valisure tested.”)
(citations omitted). “In other words, even without the high-temperature incubation testing Valisure
performed, every [Neutrogena and Clean & Clear] BPO product it tested contained benzene.”
Target Corp., 2026 WL 145824, at *5. 	And, as alleged by Plaintiffs, any amount of benzene
renders a BPO acne treatment product unsafe. (ECF No. 59 ¶¶ 46, 48.)
Defendants argue that trace amounts of benzene should not confer standing. (ECF No. 60-
1 at 38-39 (first citing Kimca v. Sprout Foods, Inc., Civ. No. 21-12977, 2022 WL 1213488 (D.N.J
Apr. 25, 2022)); and then citing Koronthaly v. L’Oreal USA, Inc., 374 F. App’x 257 (3d Cir. 2010).)
If Defendants were correct, then Plaintiffs who purchased Clean & Clear products would not have
standing because the Valisure study—regardless of incubation—only found benzene levels in those
products below the FDA 2 ppm guideline limit. 	(See ECF No. 60-2 at 40.) 	The Court finds
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 19 of 37 PageID:
<pageID>
20
Defendants’ pre-Huertas cases distinguishable and finds both Huertas and the BPO acne treatment
cases more instructive.
In Kimca, the plaintiffs argued that they were misled into purchasing baby food products
with “elevated levels of heavy metals,” and alleged the levels were elevated based on “accepted
standards.” 	Kimca, 2022 WL 1213488, at *6. 	The court found these allegations insufficient
because it was “not clear that the ‘accepted standards’ identified in the [complaint were] applicable
to baby food” as the plaintiffs alleged metal limits for water only. Id. (emphasis added). Similarly,
in Koronthaly, the Third Circuit found a plaintiff did not have standing to pursue a claim based on
lead found in the plaintiff’s lipstick. 	Koronthaly, 374 F. App’x at 258-59. 	There, the plaintiff
alleged she suffered a concrete injury because “the lipstick contain[ed] lead in far greater amounts
than permitted in candy by the FDA.” Id. at 258. But her allegations were “belied by the FDA’s
report finding that the lead levels in [the defendants’] lipsticks were not dangerous.” Id. at 259.
With nothing more, the Third Circuit “asserted only a subjective allegation that the trace amounts
of lead in the lipsticks [were] unacceptable to her, not an injury-in-fact sufficient to confer Article
III standing.” Id.
Here, Plaintiffs’ allegations are more tailored. 	For example, citing the World Health
Organization, Plaintiffs allege that “[b]enzene is a genotoxic carcinogen in human and no safe
level of exposure can be recommended.” (ECF No. 59 ¶ 46 (emphasis added).) And Plaintiffs cite
an author of the Valisure study who states that “I want to reiterate first and foremost that there is
not a safe level of benzene that can exist in any skin care product, over the counter or prescription.”
(Id. ¶ 48.) 	These allegations correspond to the thrust of Huertas, which focuses on plausibly
alleging the presence—not level—of benzene. See, e.g., 120 F. 4th at 1178 (stating a plaintiff must
“sufficiently alleg[e] that their products . . . contained benzene”) (emphasis omitted). And the
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 20 of 37 PageID:
<pageID>
21
other acne BPO cases have found similarly. See Target Corp., 2026 WL 145824, at *5 (finding
standing when plaintiffs alleged “that any amount of benzene renders a BPO acne treatment
product defective”); id. (“Plaintiffs’ primary theory is that any amount of benzene renders a BPO
acne treatment product defective. Plaintiffs allege facts plausibly showing that benzene was
present in every tested Up&Up BPO acne treatment product at day 0, before Valisure conducted
its high-temperature incubation testing.”); Howard, 2024 WL 4272931, at *3 (finding standing
when “the thrust of [p]laintiffs’ complaint is that, because of the inherent propensity of BPO to
degrade into benzene under ‘normal use, handling, and storage’ conditions, all acne products with
BPO are unsafe because they essentially all contain benzene, and any amount of benzene is
dangerous.”) 	Thus, the Court finds Plaintiffs need not have alleged Defendants’ BPO products
contained higher levels of benzene than outlined in FDA guidance to confer standing. Therefore,
because each Plaintiff purchased a Neutrogena or Clean & Clear acne BPO product, each has
alleged standing to pursue monetary damages.13
2. 	Injunctive Relief
As for injunctive relief, to satisfy Article III standing, plaintiffs “must establish that [they
are] likely to suffer future injury from [Defendants’] conduct.” Johnson & Johnson, 903 F.3d at
292 (internal quotations marks and citations omitted). 	In Johnson & Johnson, the plaintiff
purchased Johnson & Johnson’s Baby Powder, which she alleged contained talc, and sought two
forms of injunctive relief: (1) an order requiring defendants to engage in corrective advertising,
and (2) an order enjoining defendants from continuing their unlawful practices of selling Baby
13 	Accordingly, the Court also finds Plaintiffs have standing to pursue their claims for
restitution. See In re Johnson & Johnson Talcum Powder Prod. Mktg., Sales Pracs. & Liab. Litig.,
903 F.3d 278, 291-92 (3d Cir. 2018) (finding standing analysis for monetary damages and
restitution was based on “the same rationale”).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 21 of 37 PageID:
<pageID>
22
Powder without a warning of the health risks. Id. at 292. The Third Circuit concluded the plaintiff
did not have standing to pursue injunctive relief because she “makes clear in this very lawsuit that
she is well aware of health risks associated with using Baby Powder, [so] we readily conclude that
she is not likely to suffer future economic injury.” Id. As the Third Circuit explained, “[t]he law
affords [plaintiff] the dignity of assuming that she acts rationally, and that she will not act in such
a way that she will again suffer the same alleged ‘injury.’” Id. at 293; see also Howard, 2024 WL
4272931, at *5 (finding no standing for injunctive relief when plaintiffs failed to allege that they
would buy defendants’ BPO acne products in the future).
Here, Plaintiffs seek similar injunctive relief as the Johnson & Johnson plaintiff, (ECF No.
69 at 104), and it is clear they have no intention of purchasing Defendants’ BPO products in the
future. (see, e.g., ECF No. 59 ¶ 101 (“If Defendants had disclosed to Plaintiffs and putative Class
members that the BPO Products contain and/or degrade to form benzene, Plaintiffs and putative
Class members would not have purchased the BPO Products.”).) Therefore, Plaintiffs’ argument—
that a standing analysis for injunctive relief is premature—is unconvincing, and the Court
“conclude[s] that [Plainitffs] do[] not have standing to seek injunctive relief.” Johnson & Johnson,
903 F.3d at 293.14
14 	Plaintiffs also seek declaratory relief. 	(ECF No. 59 at 104.) 	But the sole reference to
declaratory relief in the Consolidated Class Action Complaint is “made in connection with
[Plaintiffs’] request for injunctive relief.” Johnson & Johnson, 903 F.3d at 292. n.19. Indeed, the
full prayer for relief with respect to declaratory relief states: “An order awarding declaratory relief,
and any further retrospective or prospective injunctive relief permitted by law or equity including
enjoining Defendants from continuing the unlawful practices alleged herein, and injunctive relief
to remedy Defendants’ past conduct.” (ECF No. 59 at 104.) Accordingly, Plaintiffs do not have
standing to pursue declaratory relief. Johnson & Johnson, 903 F.3d at 292. n.19 (“Because [the
plaintiff’s] references to ‘declaratory’ relief appear to be a mere rehashing of her requests for
injunctive relief . . . we need not repeat our standing analyses . . . .”); see also In Re Target Corp.
BPO Sales & Mktg. Litig., Civ. No. 24-1323, 2026 WL 145824, at *6 (D. Minn. Jan. 20, 2026)
(finding the plaintiffs lacked standing to pursue injunctive and declaratory relief).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 22 of 37 PageID:
<pageID>
23
B. 	Preemption and Failure to State a Claim
The parties contest whether Plaintiffs’ state statutory and common law claims are
preempted by the FDCA. (ECF No. 60-1 at 33-37; ECF No. 63 at 15-26; ECF No. 65 at 8-12.)
While the Court finds that not all of Plaintiffs’ claims are preempted, Plaintiffs have nonetheless
failed to state a claim under Rules 8 and 9.
The Supremacy Clause of the United States Constitution, U.S. Const. art. VI, cl. 2,
displaces state law that “interferes with or is contrary to federal law.” 	Pennsylvania v. Navient
Corp., 967 F.3d 273, 287 (3d Cir. 2020) (quoting Free v. Bland, 369 U.S. 663, 666, (1962)). There
are three ways that “[f]ederal law can preempt state law . . . : (1) express preemption; (2) field
preemption; or (3) conflict preemption.” Klotz v. Celentano Stadtmauer & Walentowicz LLP, 991
F.3d 458, 463 (3d Cir. 2021) (citing Farina v. Nokia Inc., 625 F.3d 97, 115 (3d Cir. 2010)). These
categories “‘are not rigidly distinct’ . . . [a]nd at least one feature unites them: Invoking some
brooding federal interest or appealing to a judicial policy preference should never be enough to
win preemption of a state law; a litigant must point specifically to ‘a constitutional text or a federal
statute’ that does the displacing or conflicts with state law.” Virginia Uranium, Inc. v. Warren, 587
U.S. 761, 767 (2019) (first quoting Crosby v. Nat’l Foreign Trade Council, 530 U.S. 363, 373 n.6
(2000); and then quoting Puerto Rico Dep’t of Consumer Affs. v. Isla Petroleum Corp., 485 U.S.
495, 503 (1988)).
Defendants also argue that Plaintiffs lack standing to bring claims on behalf of putative
class members in other states, noting the split within the Third Circuit on this issue. (ECF No. 60-
1 at 42 (citing Snowdy v. Mercedes-Benz USA, LLC, Civ. No. 23-1681, 2024 WL 1366446, at *5
(D.N.J. Apr. 1, 2024)).) 	The Court, however, need not address this argument at this early, pre-
class certification stage. See Rolland v. Spark Energy, LLC, Civ. No. 17-2680, 2019 WL 1903990,
at *5 & n.5 (D.N.J. Apr. 29, 2019).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 23 of 37 PageID:
<pageID>
24
When federal preemption is invoked, the “inquiry is guided by two principles.” Navient
Corp., 967 F.3d at 288 (citing Farina, 625 F.3d at 115). The first is that “the intent of Congress is
the ‘ultimate touchstone’ of preemption analysis.” Id. (quoting Medtronic, Inc. v. Lohr, 518 U.S.
470, 485 (1996). In discerning congressional intent, courts “look to the language, structure, and
purpose of the relevant statutory and regulatory scheme to develop a reasoned understanding of
the way in which Congress intended the statute and its surrounding regulatory scheme to affect
business, consumers, and the law.” Shuker v. Smith & Nephew, PLC, 885 F.3d 760, 771 (3d Cir.
2018) (quoting Sikkelee v. Precision Airmotive Corp., 822 F.3d 680, 687 (3d Cir. 2016)).
The second principle is “the basic assumption that Congress did not intend to displace state
law.” Navient Corp., 967 F.3d at 288 (quoting Farina, 625 F.3d at 116). “[B]ecause the States are
independent sovereigns in [the] federal system, [courts] have long presumed that Congress does
not cavalierly preempt state-law causes of action,” especially when a “state is exercising its police
power.” Id. (quoting Lohr, 518 U.S. at 485). However, when a federal statute contains an express
preemption clause or when a case arises in an area that has historically been heavily regulated by
the federal government, courts “do not invoke any presumption against pre-emption but instead
‘focus on the plain wording of the [the statute], which necessarily contains the best evidence of
Congress’ pre-emptive intent.’” 	Puerto Rico v. Franklin Cal. Tax-Free Tr., 579 U.S. 115, 125
(2016) (quoting Chamber of Com. of U.S. v. Whiting, 563 U.S. 582, 594 (2011)).15
The FDCA, which provides no private right of action, see In re Orthopedic Bone Screw
Prods. Liab. Litig., 193 F.3d 781, 788 (3d Cir. 1999), contains a broad express preemption
15 	“Preemption is an affirmative defense and therefore, dismissal under Rule 12(b)(6) is only
justified when defendant can show that preemption is ‘manifest in the complaint itself.’” Doe-1
v. LexisNexis Risk Sols., Inc., Civ. No. 24-4566, 2025 WL 306592, at *6 (D.N.J. Jan. 27, 2025)
(quoting Lupian v. Joseph Cory Holdings LLC, 905 F.3d 127, 130-31 (3d Cir. 2018)).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 24 of 37 PageID:
<pageID>
25
provision. 	That provision outlines that no state “may establish or continue in effect any
requirement—(1) that relates to the regulation of a [nonprescription drug]; and (2) that is different
from or in addition to, or that is otherwise not identical with, a requirement under” the FDCA. 21
U.S.C. § 379r(a). 	“Congress has therefore mandated that states may not create requirements
different from the FDCA’s requirements.” 	Crozier v. Johnson & Johnson Consumer Cos., Inc.,
901 F. Supp. 2d 494, 503 (D.N.J. 2012). 	The statute defines “requirement” to include “any
requirement relating to public information or any other form of public communication relating to
a warning of any kind for a drug.” 21 U.S.C. § 379r(c)(2). Courts have interpreted this provision
to mean that “virtually any state requirement that relates to the regulation of nonprescription drugs
can be preempted, regardless of the common law [or state legislative or regulatory] theory under
which it is brought.” Carter v. Novartis Consumer Health, Inc., 582 F. Supp. 2d 1271, 1282 (C.D.
Cal. 2008) (citing Riegel v. Medtronic, Inc., 552 U.S. 312, 324-25 (2008)); see also Navarro v.
Walmart, Inc., Civ. No. 24-00288, 2025 WL 3563471, at *12 (E.D. Cal. Dec. 12, 2025), report and
recommendation adopted, 2026 WL 266374 (E.D. Cal. Feb. 2, 2026). But the FDCA “does not
preempt claims under state law that impose identical or ‘parallel’ requirements to FDA regulations,
such as where a plaintiff sues over a defendant’s violation of the FDCA.” Eisman v. Johnson &
Johnson Consumer, Inc., Civ. No. 24-01982, 2025 WL 241024, at *3 (C.D. Cal. Jan. 17, 2025)
(citations omitted). Accordingly, to survive a motion to dismiss, Plaintiffs must bring state causes
of action that impose parallel requirements to those imposed by the FDCA and must plausibly
allege Defendants violated those requirements.
As relevant to this case, the FDCA and its accompanying regulations impose requirements
on Defendants stemming from four sources: 1) the Acne Monograph; 2) the format and content
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 25 of 37 PageID:
<pageID>
26
labeling requirements in 21 C.F.R. § 201.66; 3) the prohibition on adulterating or misbranding
drugs in Chapter V of the FDCA; and 4) the cGMPs in 21 C.F.R. §§ 210-211.
Defendants first argue Plaintiffs’ claims are preempted because Defendants’ practices
comply with the Acne Monograph. (ECF No. 60-1 at 33-34.) Defendants also contend that even
though Plaintiffs claim Defendants’ practices run afoul of Chapter V of the FDCA’s general
prohibitions on adulteration and misbranding, “Plaintiffs allege no wrongful factual conduct
beyond sale of BPO Acne Medications without a benzene warning” so their argument “boils down
to the untenable proposition that formulation and labeling of Acne Medication as specifically
prescribed by the FDA in the Monograph per se violates general FDCA provisions.” (Id. at 35.)
Last, Defendants argue that “Plaintiffs merely quote [the cGMPs] regulations and detail no alleged
violation other than the presence of benzene.” (ECF No. 65 at 11.) Defendants do not address the
format and content labeling requirements in 21 C.F.R. § 201.66. (See generally ECF No. 60-1;
ECF No. 65).
Plaintiffs argue their claims are not preempted because the presence of benzene in
Defendants’ BPO products is a violation of both Chapter V of the FDCA’s prohibition on
adulterated or misbranded drugs and the cGMPs, and these provisions impose requirements that
are additional to the ones imposed by the Acne Monograph. (ECF No. 63 at 17, 21.) Plaintiffs
also argue that Defendants’ BPO products contain undisclosed benzene in violation of 21 C.F.R.
§ 201.66, which requires the listing of inactive ingredients on the label. (Id. at 24.) The Court will
address each of Plaintiff’s theories of liability and evaluate whether those theories are preempted,
and if they are not, whether Plaintiffs have stated a claim.
1. 	Mislabeling or Misbranding
Plaintiffs allege that Defendants were required to disclose the presence of benzene in their
acne products and not doing so constitutes mislabeling or misbranding under 21 C.F.R. § 201.66
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 26 of 37 PageID:
<pageID>
27
and Chapter V of the FDCA. 	(ECF No. 59 ¶¶ 100-103, 124-125.)16 	It is true that the Acne
Monograph contains no such requirement. See, e.g., Howard, 2024 WL 4272931, at *8 (“[T]he
monograph sets forth in detail the exact warnings that must be on the labels of OTC acne drug
products[.] Those warnings do not include any mention of benzene or its risks.”) (citing 21 C.F.R.
§ 333.350(c)(4), (d)(2)). The more difficult question on which courts disagree is whether the other
sources of FDCA authority establish such a requirement. 	If so, then Plaintiffs’ theory would
survive if there are parallel state law requirements.
The Court begins with the requirement that OTC drug product labels must list “inactive
ingredients.” 21 C.F.R. § 201.66(c)(8). The regulation defines “inactive ingredient” to be “any
component other than an active ingredient.” 	21 C.F.R. § 201.66(b)(8). Whether benzene is an
“inactive ingredient” in Defendants’ BPO products thus turns on the definition of “component.”
While 21 C.F.R. § 201.66 does not define “component,” the term is defined in a different portion
of the same subchapter of the regulation, pertaining to manufacturing: “Component means any
ingredient intended for use in the manufacture of a drug product, including those that may not
appear in such drug product.” 	21 C.F.R. § 210.3(b)(3) (emphasis added). 	Every court to have
16 	To the extent the Consolidated Class Action Complaint alleges Defendants were required
to disclose the possibility that BPO degrades into benzene, Plaintiffs appear to have abandoned
this argument and instead stand on the benzene-in-the-products theory. (See ECF No. 63 at 17-18
(“Plaintiffs allege that the sale of BPO Products containing benzene violated state law because the
BPO Products should not have been sold with benzene in them.”); id. at 18 (“Because the BPO
Products were contaminated with benzene, they were unfit for human use and violated state law
by selling an adulterated acne product containing benzene.”).) In any event, the Court would find
such a theory preempted because such a disclosure is not required by the Acne Monograph nor do
Plaintiffs cite any other FDCA authority including such a requirement. 	Indeed, the Court has
reservations that such a theory would even be enough to establish Article III standing. See Target
Corp., 2026 WL 145824, at *5 (“I don’t understand [p]laintiffs to allege a mere possibility of
degradation . . . . In this understanding of [p]laintiffs’ liability theory, their Article III standing
would seem doubtful—if benzene contamination represented merely a risk, then we would have
nothing to show that the items [p]laintiffs purchased manifested benzene contamination.”).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 27 of 37 PageID:
<pageID>
28
addressed whether it is appropriate to apply this definition—the only definition of “component” in
the subchapter—to the labelling context has found it appropriate to do so. See Howard, 2024 WL
4272931, at *8; Navarro, 2025 WL 3563471, at *13; Bodunde v. Walgreens Boots Alliance, Inc.,
Civ. No. 24-00985, 2025 WL 1411306, at *13 (E.D. Cal. May 15, 2025); Kouyate v. Harv. Drug
Grp. LLC, Civ. No. 24-6223, 2025 WL 2773159, at *10 (S.D.N.Y. Sept. 26, 2025); Williams v.
Galderma Laby’s, L.P., Civ. No. 24-2222, 2024 WL 4213220, at *4 (N.D. Ill. Sept. 17, 2024). The
Court agrees. Because the definition requires inactive ingredients to be “intended” for use, and
because Plaintiffs do not allege Defendants intended to use benzene in their products, Defendants
were not required to list benzene on its labels under 21 C.F.R. § 201.66.
But the Court must also resolve whether Defendants were required to label benzene on
their products under Chapter V of the FDCA. A drug is misbranded “[i]f its labeling is false or
misleading in any particular.” 21 U.S.C § 352(a)(1). The labeling is “misleading” if it “fails to
reveal facts . . . material with respect to consequences which may result from the use of the article
to which the labeling or advertising relates . . . under such conditions of use as are customary or
usual.” 21 U.S.C § 321(n). Courts have come out differently on the issue of whether a plaintiff’s
misbranding theories are preempted given these provisions. In Howard, the court found the claim
was preempted, tying its analysis back to the Acne Monograph: “[d]efendants are not alleged to
have made affirmative misrepresentations outside the scope of the monograph. Instead, [p]laintiffs
allege that the Proactiv labels are misleading because they omit a warning that the monograph does
not require.” 2024 WL 4272931, at *8-9. By contrast, analyzing the same provisions and the same
theories, the Target Corporation court found the theory was not preempted: “[p]laintiffs’ state-law
misbranding theory tracks these requirements. 	They plausibly allege that benzene is present in
Up&Up acne treatment products and that benzene causes adverse health consequences. Accepting
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 28 of 37 PageID:
<pageID>
29
those allegations as true, the FDCA plausibly would have required Target to disclose benzene’s
presence in the Up&Up acne treatment products’ labeling.” 2026 WL 145824, at *10.17
The Court finds the approach in Target Corporation more convincing. The Howard court’s
analysis relies exclusively on the Acne Monograph, but the FDCA’s regulations specifically
require adherence to the applicable monograph “and . . . each of the conditions contained in this
part,” including Chapter V of the FDCA, in order to be recognized as safe, effective, and not
misbranded. 	21 C.F.R. § 330.1 (emphasis added) (outlining separate requirements from the
applicable monograph). 	Indeed, the Acne Monograph itself also recognizes that its labeling
requirements are subject to Chapter V of the FDCA. 	21 C.F.R. §§ 333.301(a), 333.350(b).
Defendants’ only response is that the Target Corporation approach—under which an entity can
comply with the Acne Monograph but still violate the FDCA’s more general requirements—is a
“reading of federal law [that] defies plausibility,” and Defendants cite a string of cases in support
of this proposition. (ECF No. 60-1 at 35-36). But Defendants cite the very same cases that the
Target Corporation court analyzed and found unpersuasive because they “stop[ped] with the
[M]onograph.” 2026 WL 145824, at *11 (collecting cases). The Court is similarly unpersuaded.
And like in Target Corporation, Plaintiffs allege that benzene is present in the Neutrogena and
Clean & Clear products and causes adverse health consequences. (ECF No. 59 ¶¶ 1, 3, 43, 46, 48,
111, 115, 123, 189, 214, 227.) 	Therefore, Plaintiffs’ claim—that Defendants were required to
disclose benzene’s presence on the product label even if the Acne Monograph contained no such
requirement—is not preempted.
17 	It appears that none of the other BPO acne treatment cases considering the preemptive
effects of the Acne Monograph have considered the FDCA’s definition of “misleading,” 21 U.S.C
§ 321(n), in the misbranding context.
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 29 of 37 PageID:
<pageID>
30
Although Plaintiffs’ Chapter V misbranding theory is not preempted, Plaintiffs must still
allege that their claims are cognizable under parallel state law. See Daugherty v. Padagis US LLC,
794 F. Supp. 3d 674, 694 (N.D. Cal. 2025) (“Plaintiffs provide a laundry list of state statutes
without demonstrating that these state regulations actually impose requirements identical to federal
ones.”). In other words, the state causes of action must themselves be parallel to 21 U.S.C § 352.
See Millman v. Medtronic, Civ. No. 14-1465, 2015 WL 778779, at *4 n.2 (D.N.J. Feb. 24, 2015)
(“To state a ‘parallel’ claim, a plaintiff must allege (1) the violation of a specific federal
requirement applicable . . . ; (2) the violation of an identical state-law duty; and (3) that the
predicate federal violation caused his or her injuries.”).
Here, Plaintiffs’ conclusory allegation that “[states] have enacted laws adopting or
mirroring th[is] federal standard[]” is insufficient to adequately plead that the state causes of action
that Plaintiffs bring in this case are parallel to 21 U.S.C § 352. (ECF No. 59 ¶ 81.) In a footnote,
Plaintiffs cite a handful of statutes—from California, Louisiana, Missouri, and New York City—
that largely track 21 U.S.C § 352. (See id. ¶ 96 n.64 (Cal. Health & Safety Code § 111330 (“Any
drug or device is misbranded if its labeling is false or misleading in any particular.”)); id. (La. Rev.
Stat. § 40:617 (“A drug or device is considered misbranded if it has been found to be such by any
department of the United States government, or . . . [i]f its labeling is false or misleading in any
particular.”)); id. (Mo. Rev. Stat. § 196.100(1) ( “Any manufacturer, packer, distributor or seller of
drugs or devices in this state shall comply with the current federal labeling requirements contained
in the [FDCA], as amended, and any federal regulations promulgated thereunder. Any drug or
device which contains labeling that is not in compliance with the provisions of this section shall
be deemed misbranded.”)); id. (N.Y.C. Health Code § 71.05(f) (“A drug shall be deemed misbranded
as set forth in the Federal [FDCA] (21 U.S.C. § 352)[.]”)).) However, Plaintiffs do not “make the[]
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 30 of 37 PageID:
<pageID>
31
direct connections” clear between these statutory provisions and the ones Plaintiffs allege
Defendants violated in their Consolidated Class Action Complaint. Navarro, 2025 WL 3563471,
at *14. 	(Compare ECF No. 59 ¶ 96 & n.64, with id. ¶¶ 160-161, 180-181, 191-200). For example,
it is unclear what relevance a statute from Louisiana has on the instant matter when no Plaintiff
resides in or purchased BPO products in Louisiana. 	(See id. ¶¶ 8-20.) And while at least two
Plaintiffs reside in Missouri, the statutory provision Plaintiffs allege Defendants violated is the
Missouri Merchandising Practices Act, Mo. Rev. Stat. § 407, et seq., (id. ¶¶ 29-30, 194), but
Plaintiffs do not explain the connection, if any, between this provision and the one setting forth
drug labeling requirements that are parallel to the FDCA. The same is true for California and New
York City. (See id. ¶¶ 149, 158, 161, 180-181, 191, 196).
And, apart from the parallelism deficiencies with respect to state statutory causes of action,
nowhere do Plaintiffs allege or otherwise explain parallelism with respect to the common law
theories of relief. See Conley v. St. Jude Med., LLC, 482 F. Supp. 3d 268, 275 (M.D. Pa. 2020)
(“In order to adequately allege a ‘parallel’ claim that would escape preemption, a plaintiff must
generally allege ‘specific violations of federal law that establish a parallel state duty’ [but]
‘[g]eneralized common law theories of liability’ do not suffice to meet this standard.”) (citing
Williams v. Cyberonics, Inc., 388 F. App’x 169, 171 (3d Cir. 2010)); Cf. Buckman Co. v. Plaintiffs’
Legal Comm., 531 U.S. 341, 350 (2001) (noting the practical issues regarding “complying with
the FDA’s detailed regulatory regime in the shadow of 50 States’ tort regimes”).18 	Because
18 	Indeed, courts that have found preemption or an inadequate pleading of parallelism with
respect to state statutes have not evaluated plaintiffs’ state common law theories. See Daugherty
v. Padagis US LLC, 794 F. Supp. 3d 674, 683, 693-96 (N.D. Cal. 2025) (not specifically evaluating
breach of the implied warranty of merchantability and unjust enrichment claims); Navarro v.
Walmart, Inc., Civ. No. 24-00288, 2025 WL 3563471, at *12 (E.D. Cal. Dec. 12, 2025) (same),
report and recommendation adopted, 2026 WL 266374 (E.D. Cal. Feb. 2, 2026).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 31 of 37 PageID:
<pageID>
32
“Plaintiffs have failed adequately to allege with specificity parallelism of each state law asserted”
with respect to the misbranding theory under 21 U.S.C § 352, Daugherty, 794 F. Supp. 3d at 694,
the claim cannot go forward.
2. 	Adulteration
Plaintiffs argue that because Defendants sold products with benzene, those products were
“adulterated” in violation of the FDCA and therefore any corresponding state claims are not
preempted. 	(ECF No. 59 ¶¶ 72-81, 90-91; ECF No. 63 at 21.) Plaintiffs allege that Defendants’
products were adulterated under 21 U.S.C. § 351(a)(2)(B). 	(ECF No. 59 ¶¶ 90. 120). 	Section
351(a)(2)(B) provides that drug products are adulterated if they do not comply with the cGMPs in
21 C.F.R. §§ 210-211. See 21 U.S.C. § 351(a)(2)(B). Thus, Plaintiffs allege Defendants did not
comply with the cGMPs because the products contain benzene, and because Defendants did not
comply, the products are adulterated. (ECF No. ¶¶ 72, 81, 90-91).
Courts generally find cGMP-based claims are not preempted in the acne BPO products
context. See, e.g., Navarro, 2025 WL 3563471, at *14 (“The Court concludes that to the extent
[p]laintiffs’ state law claims are parallel claims brought for violations of cGMPs, those claims are
not categorically preempted.”); Daugherty, 794 F. Supp. 3d at 694 (similar); Target Corp. 2026
WL 145824, at *11 (proceeding to analyze merits of cGMP claims); Williams, 2024 WL 4213220,
at *5 (finding “claim is preempted to the extent she argues [defendant] should have mentioned
benzene on [product’s] label—either as a warning or as an inactive ingredient—but is not
preempted based on [defendant’s] alleged failure to comply with cGMPs”). 	The Court sees no
reason to depart from these cases and therefore finds the cGMP claims based on the adulteration
theory are not preempted to the extent they are parallel to state cGMP provisions.
While courts that have addressed cGMP arguments find those claims are not preempted,
they have come out differently on whether plaintiffs sufficiently state a claim. 	In Navarro, the
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 32 of 37 PageID:
<pageID>
33
court advised plaintiff “to make the[] direct connections” clear between the cGMPs and state law
claims “as opposed to requiring [the defendant] and the [c]ourt to put the pieces together in a
complex pleading.” Navarro, 2025 WL 3563471, at *14. But even if parallelism were satisfied,
the court found plaintiffs failed to state a claim under Rule 8—not to mention Rule 9(b)—because
“the allegations identified by [p]laintiffs seemingly require assuming that because benzene was
later discovered in third-party testing of Walmart’s BPO products, that this necessarily, in and of
itself, leads to the plausible conclusion that Walmart failed to abide by the cGMPs . . . .” Id. at
*17. 	The court found the allegations conclusory and the logic both “missing [a] step,” and
“circular.” Id. at *17-18. In Daugherty, the court dismissed the cGMP claims because plaintiffs
failed to plead (1) the parallel state laws incorporating the cGMPs with specificity and (2) “specific
facts establishing [d]efendants’ violations of particular cGMPs and how such violations renders
the BPO [p]roducts adulterated.” 794 F. Supp. 3d at 694-96. The Target Corporation court also
found the cGMP allegations conclusory. 2026 WL 145824, at *11. However, that court separately
found the adulteration theory survived “because the at-issue products plausibly contained
benzene,” but the court tied this finding to 21 U.S.C. § 351(a)(1)—which states a product is
adulterated “if it consists in whole or part of any filthy, putrid, or decomposed substance”—instead
of the cGMPs. See id. at *3, *11.19
19 	Target Corporation did not elaborate on why 21 U.S.C. § 351(a)(1) provided a sufficient
basis for the plaintiffs’ benzene adulteration claim. 2026 WL 145824, at *11. Here, apart from a
conclusory recitation of the statute, Plaintiffs do not address whether, because Defendants’
products contain benzene, those products “consist[] in whole or part of any filthy, putrid, or
decomposed substance.” 	(ECF No. 63 at 21 (citing 21 U.S.C. § 351(a)(1).) 	To the extent they
allude to such an argument, it is in direct connection to the cGMP theory. (Id. at 11-12 (“Defendant
failed to comply with the FDA current [cGMPs] by allowing the BPO in its Products to decompose
and form benzene.”).) 	Unlike Target Corporation, the Court therefore only considers the
adulteration claim in the context of the cGMP theory and not in the isolated context of 21 U.S.C.
§ 351(a)(1).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 33 of 37 PageID:
<pageID>
34
By contrast, in Williams, the court found the plaintiff’s allegations that defendant “could
not have complied with cGMP testing and safety requirements because had they done so,
[defendant] would have detected benzene” to be sufficient. 2024 WL 4213220, at *6. The Court
recognized the “ipso facto reasoning” baked into these allegations, but instead of dismissing them
for this reason—like in Navarro, 2025 WL 3563471, at *17-18—the court found “the facts alleged
plausibly suggest [plaintiff] is entitled to relief.” Williams, 2024 WL 4213220, at *6. Accordingly,
the parallel state law claims survived. Id.
The Court finds that, even if not preempted, Plaintiffs cGMP claims fail for two reasons.
First, plaintiffs do not adequately allege parallelism. 	See Daugherty, 794 F. Supp. 3d at 694;
Navarro, 2025 WL 3563471, at *18. While Plaintiffs do allege many state statutes are parallel to
the cGMPs,20 Plaintiffs do not “make the[] direct connections,” Navarro, 2025 WL 3563471, at
*14, between those statutes and the ones under which Plaintiffs seek relief. (Compare ECF No.
59 ¶ 79, with id. ¶¶ 160-161, 180-181, 191-200.) 	For example, while it appears California has
incorporated the federal cGMP regulations, see Cal. Health & Safety Code §§ 110105, 111260,
Plaintiffs do not cite the incorporating provisions in their Consolidated Class Action Complaint,
or even in their briefing, (see generally ECF No. 59; ECF No. 63). See Daugherty, 794 F. Supp.
3d at 691 & n.4, 694-95 (noting plaintiffs cited relevant California provision in their complaint
and allowing California cGMP claims to proceed as non-preempted but nonetheless finding those
claims inadequate under Rules 8 and 9). And the Court notes that, like in Daugherty, “certain
[statutes in the pleading] appear to merely bar the sale of ‘adulterated’ drugs [but] do not
incorporate” the cGMPs. 	Id. at 694 (“Plaintiffs provide a laundry list of state statutes without
20 	Plaintiffs do not explain how the state common law claims are parallel to the cGMPs. See
Conley v. St. Jude Med., LLC, 482 F. Supp. 3d 268, 275 (M.D. Pa. 2020).
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 34 of 37 PageID:
<pageID>
35
demonstrating that these state regulations actually impose requirements identical to federal ones[.]
Plaintiffs have failed adequately to allege with specificity parallelism of each state law.”).
Therefore, Plaintiffs’ adulterated theory claims cannot move forward at this time.
Second, even if the connections were clear, the Court—like the majority of those before
it—finds the allegations too conclusory to state a claim. Like in Navarro, Plaintiffs recite a long
list of cGMPs Defendants have allegedly violated. (ECF No. 59 ¶ 88.) For the vast majority of
these, Plaintiffs provide no further elaboration. 	These recitations are therefore just legal
conclusions, and “legal conclusions do not plausibly show liability.” Target Corp., 2026 WL
145824, at *11 (citing Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)); see also Conley, 482 F. Supp.
3d at 277 (“[I]nsofar as Plaintiffs attempt to use the [c]GMPs as the basis for a parallel claim,
courts have regularly found that general citations to the [c]GMPs or federal regulations are not
specific enough to sustain a parallel claim.”) (collecting cases).
The only allegations that go beyond reciting the cGMPs verbatim are those that pertain to
testing requirements. (ECF No. 59 ¶¶ 120-127.) Plaintiffs allege Defendants:
did not adequately test the BPO Products before selling them to
consumers. Defendants’ Products are “drugs” regulated by the FDA.
As with any regulated drug, Defendants . . . must have test
procedures and processes to ensure the drug’s components (active
and inactive ingredients), and finished products are safe. Both raw
ingredient materials and finished batches must be tested before
released to the public to confirm they meet specifications for
identity, strength, quality, and purity. If testing results of the raw
materials or finished product do not conform with the specifications,
the product cannot be sold to the public. Defendants must also re-
test any Products subject to deterioration.
Defendants must also do stability testing to understand the “shelf
life” of the Products and to assign an expiration date. It is well
known in the scientific community (but not among consumers) that
certain chemical ingredients can degrade or change because of
environmental, and storage conditions such as light, moisture,
temperature, and humidity, or because of the passage of time. The
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 35 of 37 PageID:
<pageID>
36
stability testing should cover all expected distributor and consumer
storage, handling, and use conditions and must be done using
“reliable, meaningful, and specific test methods.” If stability testing
finds a drug product is not stable under expected storage or use
conditions, degrades, or create toxic byproducts, the product cannot
be sold to the public.
Had Defendants adequately tested its BPO Products for benzene, it
would have discovered that its Products contained benzene at levels
above even the FDA’s “safe harbor” exception limit of 2 ppm,
making the Products illegal to distribute, market, and sell, thus
warranting a recall.
(Id. ¶¶ 120-121, 126 (citing 21 C.F.R. §§ 211.84, 160, 166).)
These allegations do little more than summarize the cGMPs and miss a key logical step.
They assume that because the products contained benzene, as demonstrated in the Valisure study,
then Defendants failed to comply with the cGMP standards. 	But Plaintiffs nowhere plead what
testing mechanisms Defendants undertook; they simply point to the third-party testing results. As
several courts have found, this is insufficient. Navarro, 2025 WL 3563471, at *17-18 (discussing
caselaw in which “‘[r]es ipsa loquitor’ was not enough to survive the relevant FDA preemption”
under Rule 8, holding accordingly, and noting that the cGMP theory also failed under Rule 9
because “plaintiffs do not assert how Walmart violated or deviated from specific cGMP standards
and how such deviations led to the adulteration of its BPO products”) (emphasis in original); Target
Corp., 2026 WL 145824, at *11 (finding theory “that benzene’s presence in Target’s Up&Up BPO
acne treatment products resulted from Target’s violations of cGMPs” conclusory). Accordingly,
the Court dismisses Plaintiffs claims brought under the adulteration theory.
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 36 of 37 PageID:
<pageID>
37
IV. 	CONCLUSION
For the foregoing reasons, and other good cause shown, Defendants’ Motion to Dismiss
(ECF No. 60) is GRANTED. An appropriate Order follows.
Dated: February 24th, 2026
_________________________
G EORGETTE CASTNER
UNITED S TATES DISTRICT JUDGE
Case 3:24-cv-04109-GC-JBD Document 78 Filed 02/24/26 Page 37 of 37 PageID:
<pageID>

Continue your research in ChatGPT or Claude

Connect Omnilex to search the legal corpus from your AI assistant.